Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodevelopmental Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CSNK2B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CSNK2B Recombinant Protein (Wild-type & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for PPI and phosphorylation assays. |
View CSNK2B Products |
| Gene Delivery | CSNK2B Promise-ORF / Lentivirus Full-length ORF for stable cell lines, overexpression, and rescue assays. |
View CSNK2B Products |
| Benchmark Ab | Anti-CSNK2B Recombinant Antibody High-affinity positive control for Western Blot, ELISA, and IP. |
View CSNK2B Products |
| Validator | CSNK2B siRNA Set For target knockdown verification and functional phenotypic validation. |
View CSNK2B Products |
| Related Target A | CSNK2A1 The catalytic alpha subunit of Casein Kinase II. Crucial for studying CK2 holoenzyme assembly and PPI disruptors. |
View CSNK2A1 Products |
| Related Target B | CSNK2A2 The catalytic alpha-prime subunit. Important for selectivity profiling of holoenzyme inhibitors. |
View CSNK2A2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Screening | High-purity CSNK2B and CSNK2A1/A2 proteins available for robust AlphaLISA/HTRF assay setup. |
| Disease-Associated Mutant Profiling | Sequence-verified mutant CSNK2B proteins representing clinical neurodevelopmental variants. |
| Lack of Controls | Recombinant Benchmark Antibodies included for assay validation and target localization. |
| False Positives | Validated siRNA included for specificity and functional knockdown checks in cell-based assays. |
Live CSNK2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Casein Kinase II (CK2) is undergoing a major paradigm shift. Historically, drug discovery focused on the catalytic subunits (CSNK2A1/CSNK2A2) using ATP-competitive small molecules (such as Silmitasertib). However, targeting the regulatory beta subunit, CSNK2B, has emerged as a highly promising alternative to achieve pathway selectivity and avoid off-target toxicity. The race for CSNK2B therapeutics is intensifying, with major players shifting focus from traditional kinase inhibitors to Protein-Protein Interaction (PPI) disruptors and targeted protein degradation (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of the CK2 holoenzyme complex and addressing CSNK2B-associated neurodevelopmental disorders (such as Poirier-Bienvenu neurodevelopmental syndrome).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Disruptors) | Academic/Biotech Consortia | Solid Tumors, Hematological Malignancies | Holoenzyme assembly inhibition assay (Need high-purity CSNK2B & CSNK2A1 proteins) |
| PROTACs / Degraders | Targeted Therapeutics Companies | Refractory Cancers | Target ubiquitination and degradation validation (Need sequence-verified Lentivirus & siRNA) |
| Gene Therapy / AAV | Rare Disease Biotechs | Poirier-Bienvenu Syndrome (POBINS) | Functional rescue assays in CSNK2B-deficient cell models (Need Promise-ORF / Lentivirus) |